Drug middlemen illegally drive up the cost of insulin, FTC says
Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.
Watch CBS News
Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.
Some popular medications are among those getting pricier at the start of 2024, including weight-loss drugs Ozempic and Mounjaro.
Sanofi is joining the nation's two other major insulin manufacturers in offering either price caps or savings programs that lower the cost of the drugs
Starting in 2024, the Danish pharmaceutical firm will reduce the cost of several of its insulin drugs.
